Ian N Glaspole

List of Publications by Year
in descending order

82 papers	6,745 citations	159585 30 h-index	62596 80 g-index
84 all docs	84 docs citations	84 times ranked	5700 citing authors

#	Article	IF	Citations
1	Essential Features of an Interstitial Lung Disease Multidisciplinary Meeting: An International Delphi Survey. Annals of the American Thoracic Society, 2022, 19, 66-73.	3.2	17
2	Self-management for pulmonary fibrosis: Insights from people living with the disease and healthcare professionals. Patient Education and Counseling, 2022, 105, 956-964.	2.2	11
3	Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 442-453.	5.7	28
4	Biomarker signatures for progressive idiopathic pulmonary fibrosis. European Respiratory Journal, 2022, 59, 2101181.	6.7	30
5	Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia. Respirology, 2022, 27, 76-84.	2.3	10
6	Coagulation factor-XII induces interleukin-6 by primary lung fibroblasts: a role in idiopathic pulmonary fibrosis?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L258-L272.	2.9	2
7	Progressive fibrosing hypersensitivity pneumonitis: Why wait?. Respirology, 2022, 27, 192-193.	2.3	1
8	Deep Learningâ€“based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 883-891.	5.6	29
9	Top 10 research priorities for people living with pulmonary fibrosis, their caregivers, healthcare professionals and researchers. Thorax, 2021, 76, 575-581.	5.6	12
10	Diagnosis and management of connective tissue diseaseâ€associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology, 2021, 26, 23-51.	2.3	45
11	Moderate resting hypoxaemia in fibrotic interstitial lung disease. European Respiratory Journal, 2021, 57, 2001563.	6.7	6
12	Untargeted metabolomics of human plasma reveal lipid markers unique to chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Proteomics - Clinical Applications, 2021, 15, e2000039.	1.6	18
13	Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respiratory Research, 2021, 22, 125.	3.6	22
14	Benefits of a virtual interstitial lung disease <scp>multidisciplinary</scp> meeting in the face of <scp>COVID</scp>â€19. Respirology, 2021, 26, 612-615.	2.3	12
15	The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia. Quality of Life Research, 2021, 30, 2615-2632.	3.1	4
16	Inhibition of NF-Î¹B by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis. Biomedicine and Pharmacotherapy, 2021, 138, 111471.	5.6	15
17	Exposures and associations with clinical phenotypes in hypersensitivity pneumonitis: A scoping review. Respiratory Medicine, 2021, 184, 106444.	2.9	19
18	Physical activity decline is disproportionate to decline in pulmonary physiology in IPF. Respirology, 2021, 26, 1152-1159.	2.3	6

#	Article	IF	Citations
19	Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. Chest, 2021, 160, 994-1005.	0.8	20
20	High intensity interval training versus moderate intensity continuous training for people with interstitial lung disease: protocol for a randomised controlled trial. BMC Pulmonary Medicine, 2021, 21, 361.	2.0	4
21	TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respiratory Research, 2021, 8, e001127.	3.0	13
22	Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia. Australian Health Review, 2021, 45, 718-727.	1.1	2
23	A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 15-20.	1.4	29
24	Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. BMC Pulmonary Medicine, 2020, 20, 257.	2.0	9
25	Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: caseâ€“control study. Thorax, 2020, 75, 864-869.	5.6	48
26	CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 221.	3.6	23
27	Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. European Respiratory Review, 2020, 29, 200154.	7.1	22
28	The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review. European Respiratory Review, 2020, 29, 190125.	7.1	51
29	Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis. European Respiratory Journal, 2020, 56, 1902058.	6.7	3
30	Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology, 2020, 59, 2217-2225.	1.9	27
31	Peer Connect Service for people with pulmonary fibrosis in Australia: Participants' experiences and process evaluation. Respirology, 2020, 25, 1053-1059.	2.3	13
32	Ambulatory Oxygen in Fibrotic Interstitial Lung Disease. Chest, 2020, 158, 234-244.	0.8	21
33	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.8	33
34	Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry. European Respiratory Journal, 2020, 55, 1901855.	6.7	23
35	Acute exacerbations in IPF: A clarion call for collaborative research. Respirology, 2020, 25, 572-573.	2.3	0
36	Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trial. BMJ Open, 2020, 10, e040798.	1.9	9

#	Article	IF	Citations
37	Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis. Respirology, 2019, 24, 1111-1114.	2.3	14
38	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	5.6	60
39	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine,the, 2019, 7, 771-779.	10.7	65
40	Comprehensive pulmonary rehabilitation for interstitial lung disease: A consensus approach to identify core education topics. Patient Education and Counseling, 2019, 102, 1125-1130.	2.2	19
41	Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulmonary Medicine, 2019, 19, 84.	2.0	26
42	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
43	Eligibility for antiâ€fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology, 2019, 24, 988-995.	2.3	7
44	Therapeutic burden in interstitial lung disease: Lessons to learn. Respirology, 2019, 24, 566-571.	2.3	9
45	Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respiratory Medicine,the, 2019, 7, 60-68.	10.7	160
46	Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 155, 712-719.	0.8	24
47	Exertional Desaturation and Prescription of Ambulatory Oxygen Therapy in Interstitial Lung Disease. Respiratory Care, 2019, 64, 299-306.	1.6	20
48	Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Respirology, 2019, 24, 361-368.	2.3	24
49	Understanding the patient's experience of care in idiopathic pulmonary fibrosis. Respirology, 2019, 24, 270-277.	2.3	31
50	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	5.6	174
51	A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 94-103.	5.6	95
52	Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. Medical Journal of Australia, 2018, 208, 82-88.	1.7	13
53	Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine, 2018, 18, 19.	2.0	58
54	Oxygen therapy for interstitial lung disease: a systematic review. European Respiratory Review, 2017, 26, 160080.	7.1	114

#	Article	IF	Citations
55	The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax, 2017, 72, 610-619.	5.6	202
56	Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 2017, 49, 1601592.	6.7	174
57	Healthâ€related quality of life in idiopathic pulmonary fibrosis: Data from the <scp>A</scp>ustralian <scp>IPF R</scp>egistry. Respirology, 2017, 22, 950-956.	2.3	85
58	Cough is less common and less severe in systemic sclerosisâ€associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology, 2017, 22, 1592-1597.	2.3	28
59	Portable oxygen concentrators versus oxygen cylinder during walking in interstitial lung disease: <scp>A</scp> randomized crossover trial. Respirology, 2017, 22, 1598-1603.	2.3	19
60	Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1700168.	6.7	32
61	Treatment of idiopathic pulmonary fibrosis in <scp>A</scp>ustralia and <scp>N</scp>ew Zealand: <scp>A</scp> position statement from the <scp>T</scp>horacic <scp>S</scp>ociety of <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand and the <scp>L</scp>ung <scp>F</scp>oundation <scp>A</scp>ustralia. Respirology, 2017, 22, 1436-1458.	2.3	39
62	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	6.7	75
63	The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology, 2017, 22, 1459-1472.	2.3	41
64	Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2017, 5, 33-41.	10.7	240
65	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, 71, 429-435.	5.6	151
66	Clinical impact of the interstitial lung disease multidisciplinary service. Respirology, 2016, 21, 1438-1444.	2.3	84
67	Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres. BMC Pulmonary Medicine, 2016, 16, 22.	2.0	45
68	Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. European Respiratory Journal, 2016, 47, 243-253.	6.7	349
69	Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respiratory Research, 2016, 3, e000105.	3.0	96
70	Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 196-201.	0.8	35
71	Be honest and help me prepare for the future. Chronic Respiratory Disease, 2015, 12, 93-101.	2.4	71
72	<scp>A</scp>ustralian <scp>I</scp>diopathic <scp>P</scp>ulmonary <scp>F</scp>ibrosis <scp>R</scp>egistry: Vital lessons from a national prospective collaborative project. Respirology, 2014, 19, 1088-1091.	2.3	32

#	Article	IF	Citations
73	Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology, 2014, 19, 1215-1221.	2.3	124
74	Comment on: A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis: reply. Rheumatology, 2014, 53, 1155-1155.	1.9	1
75	A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2083-2092.	27.0	2,959
76	Prevalence and prognosis of unclassifiable interstitial lung disease. European Respiratory Journal, 2014, 43, 1529-1530.	6.7	33
77	A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology, 2013, 52, 2302-2304.	1.9	21
78	Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respiratory Medicine, 2012, 106, 429-435.	2.9	109
79	Clinical Allergy to Hazelnut and Peanut: Identification of T Cell Cross-Reactive Allergens. International Archives of Allergy and Immunology, 2011, 155, 345-354.	2.1	20
80	Review Series: Aspects of Interstitial lung disease: Differentiating between IPF and NSIP. Chronic Respiratory Disease, 2010, 7, 187-195.	2.4	11
81	Anaphylaxis to lemon soap: citrus seed and peanut allergen cross-reactivity. Annals of Allergy, Asthma and Immunology, 2007, 98, 286-289.	1.0	28
82	P073 <break /> The role of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis.. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	0